key: cord-0873303-ffdbavwt
authors: Santos, José Diogo; Vitorino, Inês; Reyes, Fernando; Vicente, Francisca; Lage, Olga Maria
title: From Ocean to Medicine: Pharmaceutical Applications of Metabolites from Marine Bacteria
date: 2020-07-28
journal: Antibiotics (Basel)
DOI: 10.3390/antibiotics9080455
sha: fa5c6e29eccc718800f7695109885adec3f18c2e
doc_id: 873303
cord_uid: ffdbavwt

Oceans cover seventy percent of the planet’s surface and besides being an immense reservoir of biological life, they serve as vital sources for human sustenance, tourism, transport and commerce. Yet, it is estimated by the National Oceanic and Atmospheric Administration (NOAA) that eighty percent of the oceans remain unexplored. The untapped biological resources present in oceans may be fundamental in solving several of the world’s public health crises of the 21st century, which span from the rise of antibiotic resistance in bacteria, pathogenic fungi and parasites, to the rise of cancer incidence and viral infection outbreaks. In this review, health risks as well as how marine bacterial derived natural products may be tools to fight them will be discussed. Moreover, an overview will be made of the research pipeline of novel molecules, from identification of bioactive bacterial crude extracts to the isolation and chemical characterization of the molecules within the framework of the One Health approach. This review highlights information that has been published since 2014, showing the current relevance of marine bacteria for the discovery of novel natural products.

With the increase of global travel and the incorrect and excessive use of antibiotics, namely for animal production, a drastic rise in antibiotic resistance is being observed in bacterial populations throughout the world [1] . Infections with resistant organisms not only entail higher morbidity and mortality, but are also more expensive to treat and result in longer hospital stays, which places a greater burden on healthcare systems [2] . These facts make the rise in antibiotic resistance one of the greatest health challenges of the century. Based on World Health Organization (WHO) reports on the global rise of resistance in pathogenic bacteria, the Global Antimicrobial Resistance Surveillance System (GLASS) report [3, 4] forecasts an alarming future for humankind. Patients with third-generation cephalosporin-resistant Escherichia coli infections have experienced a two-fold increase in mortality attributable to bacterial infections and a significant mortality increase is also observed in patients with methicillin-resistant Staphylococcus aureus infections. Facts like these point to the imperative need for the discovery of novel antibiotics to fight these super bacteria. Moreover, the global by Sumerians and Egyptians to treat inflammation and pain. In 1852 acetylsalicylic acid was first synthesised and in 1899, Bayer patented it as aspirin [39] . Ever since then, many terrestrial organisms and in particular plants have been sought for use as natural products. It was only around the 1970s, that attention was first given to the ocean as a source of useful natural products. As the oceans cover most of the Earth's surface, they are home to a substantial portion of the world's biodiversity [40] which lives in distinctive and varied conditions and has evolved through a long period of metabolic adaptations. When exploration of the ocean's biodiversity and metabolic richness began, it resulted in the discovery of thousands of structurally unique bioactive marine natural products [41] .

Initially, the exploitation of marine wildlife for natural bioactive products focused on a small number of organisms which included sponges, molluscs, tunicates and macroalgae [42] . These were shown to produce a very diverse range of unique molecular structures, like halogenated terpenes, polyketides and prostaglandins [43] [44] [45] [46] . This diversity of bioactive structures is considered to be part of the defence, survival and predatorial strategies employed by these organisms, such as, for example, sponges, which are sessile, soft-bodied organisms, lacking morphological defences like biological armature or spines [47] . Thus, these organisms appeared to be a great source for the discovery of novel bioactive molecules. However, the bioactive molecules produced by these organisms can be present in quite small amounts. For example, halichondrin B (1) (Figure 1 ), a macrolide first isolated from Halichondria okadai that has potent anticancer activity, impeding mitotic division by targeting tubulin [48] , is present in concentrations as low as 400 µg per kg wet weight of tissue of Lissodendoryx sp. [49] . Due to their low concentrations of bioactive molecules the use of these organisms poses environmental problems, because high quantities of organisms would be needed to produce enough molecules to even begin preclinical trials [50] . Yet, its structure inspired a synthetic analogue, eribulin mesylate, which is now used in breast cancer and lipocarcinoma treatment [51] . As such, sponges, molluscs, tunicates and macroalgae still remain relevant sources of new marine natural products [52] .

The exploitation of other sources of bioactive marine organisms, mainly microorganisms, has also led to the discovery of new promising leads. Indeed, some of the molecules associated with macroorganisms such as sponges, may have their origin in associated microorganisms [53] . This may be the case of bryostatins, found in the marine bryozoan Bugula neritina [54] . The bryostatins, exemplified by bryostatin 1 (2) are polyketide macrolactones with neurological and anticancer properties that work by modulating the activity of the protein kinase C family and they were first isolated from this bryozoan in 1982 [55] . Yet, these macrolactones appear to be synthesised by a group of PKS genes of bacterial origin, indicating that bryostatins are produced by a bacterium [56] .

Marine microorganisms, like members of Actinobacteria, Proteobacteria, Firmicutes, Cyanobacteria, fungi and dinoflagellates, have shown to be great reservoirs of bioactive molecules [52] . Yet, even though initial predictions pointed to an immediate increase in the number of natural products discovered with the shift in focus from macroorganisms to microorganisms, this did not occur [57] . However, advances in the isolation of novel taxa, provided a boost in the discovery of novel bioactive molecules. Analysis of the literature reveals an increase in the number of new molecules discovered in all microorganisms from 2014 to 2018 [52] , with a special emphasis on fungi and bacteria. Members of the genus Salinospora (Actinobacteria) are examples of bacteria that lead to the discovery of salinosporamide A (3) [58] . This molecule has a potent cytotoxic activity due to a unique functionalisation of the core-fused γ-lactam-β-lactone bicyclic ring, which contributes significantly to its activity [59] . Salinosporamide A is now in phase III clinical trials for the treatment of multiple myeloma under the brand name Marizomib [60] .

tubulin [48] , is present in concentrations as low as 400 µ g per kg wet weight of tissue of Lissodendoryx sp. [49] . Due to their low concentrations of bioactive molecules the use of these organisms poses environmental problems, because high quantities of organisms would be needed to produce enough molecules to even begin preclinical trials [50] . Yet, its structure inspired a synthetic analogue, eribulin mesylate, which is now used in breast cancer and lipocarcinoma treatment [51] . As such, sponges, molluscs, tunicates and macroalgae still remain relevant sources of new marine natural products [52] . 1), a macrolide first isolated from H. okadai but also present in other sponges. Bryostatin 1 (2) , which belongs to a family of polyketide macrolides first identified in the marine bryozoan B. neritina. Salinosporamide A (3), is a proteasome inhibitor isolated from bacteria from the genus Salinospora and is in phase III clinical trials for the treatment of multiple myeloma.

The exploitation of other sources of bioactive marine organisms, mainly microorganisms, has also led to the discovery of new promising leads. Indeed, some of the molecules associated with macroorganisms such as sponges, may have their origin in associated microorganisms [53] . This may be the case of bryostatins, found in the marine bryozoan Bugula neritina [54] . The bryostatins, exemplified by bryostatin 1 (2) are polyketide macrolactones with neurological and anticancer properties that work by modulating the activity of the protein kinase C family and they were first isolated from this bryozoan in 1982 [55] . Yet, these macrolactones appear to be synthesised by a group of PKS genes of bacterial origin, indicating that bryostatins are produced by a bacterium [56] . 1), a macrolide first isolated from H. okadai but also present in other sponges. Bryostatin 1 (2) , which belongs to a family of polyketide macrolides first identified in the marine bryozoan B. neritina. Salinosporamide A (3), is a proteasome inhibitor isolated from bacteria from the genus Salinospora and is in phase III clinical trials for the treatment of multiple myeloma.

Although salinosporamide A is the best example of the potential present in bacteria, many novel molecular structures are discovered each year. In fact, in 2016, 179 new natural products of marine bacterial origin were discovered [61] , in 2017, the number rose to 242 [62] and in 2018 a total of 240 new molecules were reported [52] . The upwards trend seen in the number of discovered molecules and the remarkable chemical diversity displayed, which ranges from peptides, siderophores and polyketides to esters, macrolactones, quinones and terpenes, shows the bacterial potential for the discovery of novel active principles.

Bacteria are promising sources for novel antimicrobial natural product discovery. This is primarily due to two factors. One is their variable and malleable metabolism [63] and the other is their competitive pressure for resources against other microbes. Several recent examples of natural products from marine bacteria are provided below. The novel molecule bacicyclin (4) (Figure 2 ), which is a cyclic peptide, was isolated from a Bacillus sp. strain BC028 isolated from the common mussel (Mytilus edulis) [64] . It displays antibacterial activity against E. faecalis and S. aureus with minimal inhibitory concentration (MIC) values of 8 and 12 µM, respectively, and can help in the design of analogues with increased antibiotic efficacy [64] . Anthracimycin B (5), a polyketide with powerful anti-Gram-positive bacteria activity that was obtained from a marine-derived Streptomyces cyaneofuscatus M-169, has expanded the knowledge of how the methyl group at C-2 of anthracimycins plays a role in its antibacterial effect [65] . Taromycin B (6), a lipodepsipeptide with potent activity against methicillin-resistant S. aureus and vancomycin-resistant E. faecium which was isolated from the marine actinomycete Saccharomonospora sp. CNQ-490, provides a promising start for the development of novel antibacterial scaffoldings [66] . Janthinopolyenemycin A (7) and B (8) are also polyketides and the first examples of molecules of their structural type. Janthinopolyenemycins were isolated from the proteobacterium Janthinobacterium spp., strains ZZ145 and ZZ148, and have activity against Candida albicans [67] . Streptoseomycin (9), a macrolactone isolated from the actinobacterium Streptomyces seoulensis A01, has specific activity against microaerophilic bacteria, specially the pathogen H. pylori [68] . This restricted activity makes streptoseomycin a good starting point for the discovery of antibiotics for the treatment of H. pylori infections. The polyketides ansalactams B (10), C (11) and D (12) are highly modified ansamycins that show weak and mild anti-methicillin-resistant S. aureus and were identified in cultures of Streptomyces sp. CNH189, isolated from marine sediments. Ansalactams B and D are cyclic polyketides with similarities to ansalactam A. However, ansalactam D shows evidence of an uncommon oxetane ring. Ansalactam C is an open polyketide chain resulting from a Baeyer-Villiger-type oxidation [69] . Micromonohalimanes A (13) and B (14) are rare halimane-type diterpenoids isolated from the actinobacterium Micromonospora sp. WMMC-218. Micromonohalimane A displays a very weak inhibitory effect on methicillin-resistant S. aureus while micromonohalimane B displays moderate bacteriostatic activity against it. Xestostreptin (15) is a modified diketopiperazine isolated from Streptomyces sp. S.4, resulting from the condensation of the aminoacids threonine and alanine [70] . Xestostreptin shows weak activity against the malarial agent P. falciparum. Two macrolides, branimycins B (16) and C (17) were identified from a fermentation of the actinobacterium Pseudonocardia carboxydivorans M-227, isolated from deep sea water [71] . Branimycin B shows moderate antibacterial activity against Gram-positive bacteria, while branimycin C displayed moderate antibacterial activity against Gram-negative bacteria.

Utilizing a genome-assisted discovery strategy, three macrolactams, lobosamides A (18), B (19) and C (20) , were isolated from Micromonospora sp. RL09-050-HVF-A [72] . Lobosamides A and B showed bioactivity against the microbial agent of African trypanosomiasis, Trypanosoma brucei in low concentrations. However, lobosamide C was not bioactive. Schulze and colleagues [73] also identified salinipostins A-K bicyclic phosphotriesters isolated from the actinobacterium Salinispora sp. RLUS08-036-SPS-B with potent and selective activity against P. falciparum. The salinipostin scaffold considerably differs from any of the known antimalarial compounds, representing a novel lead structure in the development of therapeutics for malaria. Experiments with salinipostin A (21), the most bioactive of the 11 salinipostins, indicate that it exhibits growth stage-specific effects and no apparent resistance could be identified in parasite populations. A hybrid peptide-polyketide, mollemycin A (22) (Figure 3 ) was isolated from the marine bacterium Streptomyces sp. CMB-M0244 and shows potent antimalarial and broad antibacterial activities [74] . Actinosporin A (23) is a glycosilated polyketide which shows antiparasitic activity against T. brucei and was isolated from a marine sponge associated Actinokineospora sp. EG49 [75] . Likewise, actinosporin B, was also isolated but showed no bioactivity, suggesting that actinosporin A is acting selectively against the parasite. The linear lipopetides, gageopeptides A-D (24) (25) (26) (27) , gageotetrins A-C (28-30) and gageostatins A-C (31-33) were isolated from the marine Bacillus subtilis 109GGC020. These lipopetides showed a range of different antimicrobial bioactivities, with gageostatins A, B and C all showing good antimicrobial activity and moderate cytotoxic activity to lung cancer cell line NCI-H23 [76] . Gageotetrins A, B and C showed potent antimicrobial bioactivities but not cytotoxic effect on human myeloid leukaemia K-562 [77] . Furthermore, gageopeptides A, B, C and D all showed good antifungal and moderate broad antibacterial activity, while not showing cytotoxicity to human myeloid leukaemia K-562 and mouse leukemic macrophage RAW 264.7 cell lines [78] .

Antibiotics 2020, 9, x FOR PEER REVIEW 6 of 32 aminoacids threonine and alanine [70] . Xestostreptin shows weak activity against the malarial agent P. falciparum. Two macrolides, branimycins B (16) and C (17) were identified from a fermentation of the actinobacterium Pseudonocardia carboxydivorans M-227, isolated from deep sea water [71] . Branimycin B shows moderate antibacterial activity against Gram-positive bacteria, while branimycin C displayed moderate antibacterial activity against Gram-negative bacteria. 

It is estimated that as many as 10 31 viruses inhabit the oceans [79] , with concentrations ranging from 3 × 10 6 viruses mL −1 in deep sea waters to 10 8 viruses mL −1 in coastal waters [80] , many of which 

It is estimated that as many as 10 31 viruses inhabit the oceans [79] , with concentrations ranging from 3 × 10 6 viruses mL −1 in deep sea waters to 10 8 viruses mL −1 in coastal waters [80] , many of which are bacteriophages. Consequently, marine bacteria are subjected to evolutionary pressure to develop defences against viral attacks. As such, marine bacteria may be great reservoirs of antiviral leads.

A number of examples of marine bacterial natural products with antiviral bioactivities have been recently reported. Three novel abyssomicin monomers, neoabyssomicins D (34) (Figure 4 ), E and A2 and two dimers-neoabyssomicins F (35) and G (36)-were isolated from the marine Streptomyces koyangensis SCSIO 5802, with neoabyssomicin D showing moderate anti-herpes simplex virus activity, and neoabyssomicins F and G showing low activity against vesicular stomatitis virus [81] . Streptomyces sp. OUCMDZ-3434, isolated from the marine alga Enteromorpha prolifera, was shown to produce five new phenolic polyketides [82] . Of these molecules, wailupemycin J (37) and (R)-wailupemycin K (38) proved to be bioactive against the influenza A virus (H1N1). The indolosesquiterpenoids xiamycins C (39), D (40) and E (41) were isolated from the marine-derived Streptomyces sp. #HK18, and showed strong inhibitory effect against the coronavirus porcine epidemic diarrhoea virus [83] . As such, xiamycins may provide useful leads in the development of antivirals with broader spectrum activity against other coronaviruses.

Antibiotics 2020, 9, x FOR PEER REVIEW 9 of 32 are bacteriophages. Consequently, marine bacteria are subjected to evolutionary pressure to develop defences against viral attacks. As such, marine bacteria may be great reservoirs of antiviral leads. A number of examples of marine bacterial natural products with antiviral bioactivities have been recently reported. Three novel abyssomicin monomers, neoabyssomicins D (34) (Figure 4 ), E and A2 and two dimers-neoabyssomicins F (35) and G (36)-were isolated from the marine Streptomyces koyangensis SCSIO 5802, with neoabyssomicin D showing moderate anti-herpes simplex virus activity, and neoabyssomicins F and G showing low activity against vesicular stomatitis virus [81] . Streptomyces sp. OUCMDZ-3434, isolated from the marine alga Enteromorpha prolifera, was shown to produce five new phenolic polyketides [82] . Of these molecules, wailupemycin J (37) and (R)wailupemycin K (38) proved to be bioactive against the influenza A virus (H1N1). The indolosesquiterpenoids xiamycins C (39), D (40) and E (41) were isolated from the marine-derived Streptomyces sp. #HK18, and showed strong inhibitory effect against the coronavirus porcine epidemic diarrhoea virus [83] . As such, xiamycins may provide useful leads in the development of antivirals with broader spectrum activity against other coronaviruses. 

As with antimicrobials, it is ascertained that marine bacteria are great reservoirs for cytotoxic natural products. While salinosporamide A, already mentioned above, is a great example of marine cytotoxic drug discovery [58] , every year, novel anticancer bioactive structures are discovered. Actinobacteria, especially those of the genera Streptomyces and Micromonospora, have been a very prolific source of cytotoxic compounds. There are several recent examples of structures isolated from these bacteria. Dentigerumycin E (42) (Figure 5 ), is a cyclic hexapeptide bearing three piperazic acids and a pyran-bearing polyketide acyl chain, isolated from the marine actinoabcterium Streptomyces albogriseolus JB5 [84] . It showed moderate cytotoxicity against lung carcinoma A549, colorectal cancer HCT116, breast cancer MDA-MB-231, liver cancer SK-HEP-1 and stomach cancer SNU638 cell lines, while not being cytotoxic to the normal human breast epithelial cell line MCF-10A [84] . Likewise, neothioviridamide (43) is a polythioamide cyclic peptide with strong cytotoxicity against human ovarian adenocarcinoma (SKOV-3), malignant pleural mesothelioma (Meso-1) and immortalized human T lymphocyte (Jurkat) cell lines [85] . It was isolated after discovery of a novel biosynthetic cluster (thioviridamide-like biosynthetic gene) in Streptomyces sp. MSB090213SC12 by genome mining and heterologous expression of a bacterial artificial chromosome in Streptomyces avermitilis SUKA. Three cyclic depsipeptides, rakicidins G-I (44) (45) (46) , isolated from the marine actinobacterium 

As with antimicrobials, it is ascertained that marine bacteria are great reservoirs for cytotoxic natural products. While salinosporamide A, already mentioned above, is a great example of marine cytotoxic drug discovery [58] , every year, novel anticancer bioactive structures are discovered. Actinobacteria, especially those of the genera Streptomyces and Micromonospora, have been a very prolific source of cytotoxic compounds. There are several recent examples of structures isolated from these bacteria. Dentigerumycin E (42) (Figure 5) , is a cyclic hexapeptide bearing three piperazic acids and a pyran-bearing polyketide acyl chain, isolated from the marine actinoabcterium Streptomyces albogriseolus JB5 [84] . It showed moderate cytotoxicity against lung carcinoma A549, colorectal cancer HCT116, breast cancer MDA-MB-231, liver cancer SK-HEP-1 and stomach cancer SNU638 cell lines, while not being cytotoxic to the normal human breast epithelial cell line MCF-10A [84] . Likewise, neothioviridamide (43) is a polythioamide cyclic peptide with strong cytotoxicity against human ovarian adenocarcinoma (SKOV-3), malignant pleural mesothelioma (Meso-1) and immortalized human T lymphocyte (Jurkat) cell lines [85] . It was isolated after discovery of a novel biosynthetic cluster (thioviridamide-like biosynthetic gene) in Streptomyces sp. MSB090213SC12 by genome mining and heterologous expression of a bacterial artificial chromosome in Streptomyces avermitilis SUKA. Three cyclic depsipeptides, rakicidins G-I (44) (45) (46) , isolated from the marine actinobacterium Micromonospora chalcea FIM 02-523, have potent cytotoxic activity against the human pancreatic cancer cell line PANC-1 and human colon carcinoma cell line HCT-8 [86] . Rakicidins G-I differ in the length of their β-hydroxy fatty acid moiety. The 26-membered polyene macrolactam, FW05328-1 (47), isolated from Micromonospora sp. FIM05328, has potent bioactivity against three cells lines of human oesophageal squamous cell carcinoma (KYSE30, KYSE180 and EC109) [86] . The integration of genomic data in association with nuclear magnetic resonance (NMR) analysis allowed the determination of the stereostructure of neaumycin B, a cytovaricin-ossamycin-oligomycin macrolide, that was isolated from Micromonospora sp. CNY-010 [87] . Neaumycin B (48) has shown potent anti-human glioblastoma cell line U87 activity but it is unstable. Through genetic manipulation of promoters, six new polyketides, pactamides A-F, were isolated from Streptomyces pactum SCSIO 02999. Pactamides B-F showed low to moderate cytotoxic activity against human glioblastoma cell line (SF-268), human breast cancer cell (MCF-7), human large-cell lung carcinoma (NCI-H460) and human liver cancer cell (HepG2) while pactamide A (49) showed potent activity [88] . Two cyclodepsipeptides, streptodepsipeptides P11A (50) and P11B (51), were isolated from Streptomyces sp. P11-23B and displayed potent anti-proliferative bioactivity in four cell lines of human glioblastoma (U251, U87-MG, SHG-44 and C6) [89] . Research with Streptomyces sp. strain THS-55 yielded four new antimycin alkaloids, antimycins E-H (52-55), which showed potent cytotoxic effect on HPV-transformed human cervix adenocarcinoma (HeLa) cells and moderate anti-proliferative activity in human cervical cancer cell SiHa, human myelogenous leukaemia cell line K562, and human leukaemia cell line HL-60 [90] . However, cytotoxic effects were shown in healthy human embryonic kidney cells 293T. In a knockout mutant of Streptomyces sp. CHQ-64, two new alkaloids, geranylpyrrol A and piericidin F (56), were discovered [91] . Of these, piericidin F showed potent anti-proliferative activity against several cancer cell lines, including HeLa, human acute promyelocytic leukaemia (NB4) and human lung carcinoma (A549 and H1975).

Two new chromodepsipeptides, neo-actinomycin A (57) ( Figure 6 ) and neo-actinomycin B (58) were isolated from a marine-derived Streptomyces sp. IMB094 [92] . They showed strong cytotoxic effect on human colorectal carcinoma cell line HCT116 and human lung carcinoma cell line A549.

Two new macrolides, PM100117 (59) and PM100118 (60) were isolated from a marine Streptomyces caniferus GUA-06-05-006A [93] . Both PM100117 and PM100118 show potent cytotoxic effect on human breast adenocarcinoma (MDA-MB-231), human lung carcinoma (A549) and human colorectal carcinoma (HT-29) cell lines. The study of a symbiotic Streptomyces sp. (strain 1053U.I.1a.3b) of cone snails lead to the isolation of two lobophorins, H and I [94] . Lobophorins are a large family of spirotetronates with antimicrobial and cytotoxic bioactivities. Of these, lobophorin I (61) showed potent cytotoxic activity against human T-cell leukaemia cell line CEM-TART.

Besides Actinobacteria, other marine bacterial phyla are also proving to be relevant for the isolation of novel bioactive molecules. As a result of a hybrid polyketide synthase (PKS) and non-ribosomal peptide synthetase (NRPS) biosynthesis, haliamide (62) was isolated from a marine myxobacterium, Haliangium ochraceum SMP-2, and shows moderate cytotoxicity towards the HeLa cell line [95] . A novel cytotoxic indole, tetra(indol-3-yl)ethenone (63) was isolated from the marine proteobacterium Pseudovibrio denitrificans BBCC725 [96] . Tetra(indol-3-yl)ethenone has moderate cytotoxicity to human lung carcinoma cell line A549 and the mouse fibroblasts cell line L929. Another marine proteobacterium, Labrenzia sp. PHM005 produced a new tetrahydropyran-core polyketide and analogue of pederin [97] . All these examples show the great potential displayed by marine bacteria which reveals the extraordinary chemical diversity of their metabolism. When analysing the bioactive bacteria and their taxonomic groups, Actinobacteria proved to be the most prolific and diverse producers (Tables 1-3) . However, ignoring other less studied phyla denies access to valuable chemical diversity, which is essential in the drug discovery process. Moreover, marine bacterial metabolites have shown to have potential as treatment in both human and animal pathologies. Thus, marine bacterial natural products have great significance under the "One Health" framework. Two new chromodepsipeptides, neo-actinomycin A (57) ( Figure 6 ) and neo-actinomycin B (58) were isolated from a marine-derived Streptomyces sp. IMB094 [92] . They showed strong cytotoxic effect on human colorectal carcinoma cell line HCT116 and human lung carcinoma cell line A549. 

Traditional screening methodologies for antimicrobials are based on agar diffusion assays, with the Kirby-Bauer diffusion assay being the most commonly used. This assay was standardized in the 1960s by Kirby and colleagues [98] and this and other variations of agar diffusion assays are, in fact, the models currently used by the Clinical Laboratory Standards Institute (CLSI) for antimicrobial susceptibility. The diffusion assays consist of the inoculation of specific agar media, usually Mueller-Hinton or Mueller-Hinton II agar, with the pathogenic strains under test. Paper filters impregnated with the substance to be tested are then placed on top of the medium surface and the culture is incubated usually at 37 • C, for 4 to 10 h. After this period, the medium is inspected for the formation of circular spots without bacterial growth, designated inhibition halos, and their radiuses are measured and compared to reference values of other antimicrobials, as instructed by the CLSI [99] . The Kirby-Bauer diffusion assay is very simple and relatively low-cost assay, and it allows for a rapid testing of a considerable number of pathogens and bioactive antimicrobial principles. However, it offers no information on the potential bactericidal or bacteriostatic effect produced by the molecule being tested. Moreover, diffusion in the agar medium is size-dependent, meaning that for large molecules [100] , antimicrobial susceptibility may be underestimated or that false negatives can be obtained. Likewise, although there are reports of the successful use of these assays in fungi [101] , not all microorganisms can be tested, as it is the case for fastidious, slow-growing and microaerophiles bacteria. Furthermore, the impossibility of its automation also hampers use of this assay in large-scale drug discovery [102] .

Regarding antiparasitics, as parasites are usually obligate intracellular, they cannot be tested in agar diffusion assays. Therefore, the discovery of these drugs relies on the use of either cultures of parasites or in vivo treatments. Direct treatment of sick patients can be a useful tool, as it allows several different interactions to occur, like host related immunity or metabolism or the possibility of re-infection. However, direct treatment come with critical disadvantages, ranging from limited testing capacity to possible dangerous side effects for the patients. However, most antiparasitic therapeutics come from the veterinary world, as this saves human patients from contact with potentially toxic substances, while maintaining all the advantages of the direct treatment. Nevertheless, it can still be a costly endeavour and may yield results which do not prove to be suitable for human treatment [103] . In vitro culturing of parasites can be done with free living or infectious parasites. Free living parasites can be cultivated in axenic cultures [104] while infectious parasites come from intracellular infection of a host cell and which are more physiologically relevant [105] . By isolating the parasites from the host, the interferences caused in in vivo cultures are excluded. Yet, inactive drug precursors that must be activated by the host or drugs which activity require the synergistic effect of the host immunity cannot be tested. Moreover, in vitro testing is more resource intensive, making it hard to apply in the regions that are most affected by these diseases [103] .

Vaccines, as a prophylactic approach, are the primary strategy for controlling viral outbreaks and even successfully contributing to total eradication of the agent responsible [106] . However, post-infection treatments are also needed, mostly due to the high pathogenicity that current pandemic-responsible virus displays, as stated previously [20] [21] [22] [23] . The urgency for new and innovative antiviral therapeutics is also reinforced by the quick mutation rate of viral strains, which often leads to the creation of unique and drug-resistant viruses [107] .

Successful infection by a virus is dependent on various key steps, such as the kind of entry in the host cell and the genome replication [108] . Traditional screenings for evaluating promising antiviral compounds were firstly based on non-specific approaches like the plaque inhibition assay [109] , which still plays an important role in the determination of viral inhibitory concentrations. The general premise is simple, as it is based on the incubation of viral plaque-forming units in plates with overlaid layers containing media, the host cells, and the drug to be tested. The formed plaques are then stained, normally with neutral red, and counted [110] . Several modified versions of the assay have already been developed [111] [112] [113] . Nevertheless, antiviral screenings have progressed to more specific approaches, by focusing on the obtainment of bioactive molecules with high specificity to affect particular steps in the virus cell cycle [24] . This approach, which focuses on the obtainment of highly specific molecules, is seen in a variety of in vitro cell based and biochemical assays [108] . Reporter proteins such as luciferase or β-galactosidase can be incorporated in the assay [114] [115] [116] .However, to do so, a virus containing a copy of a related luciferase or a-galactosidase reporter gene in its genome is needed.

As viruses will always need to be cultivated in host cells, complementary cytotoxic studies of the potential antiviral drug (detailed in the next section) are also necessary to guarantee its non-cytotoxic effect against the cell utilized in the screening.

The first anti-cancer therapeutics came about from in vivo experimentations, as was the case of, for example, methotrexate [117] . As already stated, these assays have disadvantages, such as toxic side effects on patients or the low number of individuals and molecules tested. The introduction of the first cultivable immortalized cancer cell lines [118] lead to a great increase in the number of discovered therapeutics, by allowing more bioactive molecules to be safely tested. In vitro cytotoxicity testing is usually performed utilizing six techniques for the evaluation of molecule bioactivity. One is staining for viable cells, as in the sulphorhodamine assay [119] and another is dye exclusion, where only dead or damaged cells are stained, as is the case of Trypan Blue [120] . Cytotoxic activity can also be assessed through metabolic activity, or a lack thereof, viability of protease activity, clonogenic capability and DNA synthesis. Methods based on metabolic activity usually rely on reduction reactions, namely the reduction of tetrazolium salts [121] and the resazurin reduction assay [122] , or on the measurement of adenosine triphosphate levels, that drop as cells die [123] . In protease viability assays, cell viability is assessed by measuring the intracellular or extracellular protease activity. In intracellular protease assays, viability is positively correlated with protease activity and are performed with fluorogenic protease substrates that can penetrate cell membranes. However, in extracellular protease assays, the viability is negatively correlated with protease activity and are performed with fluorogenic protease substrates that cannot penetrate cell membranes [124] . The clonogenic capability of a cell is its ability to proliferate indefinitely, and the loss of this capacity can be related to the antitumor capacity of compounds [125] . When cells proliferate, DNA must be synthesised. In this case, quantifying the de novo synthesis of DNA is one of the most reliable and accurate proliferation assays. This can be done by incubation of cells with radioactive labels like 3 H or specific thymidine analogues that can be detected though immunoblotting [126] .

As mentioned earlier, the described bacterial bioactive secondary metabolites demonstrate a high degree of chemical and structural diversity and complexity. As these molecules do not appear to participate directly in the growth and development of the organism but are often important for other actions like stress response, competition or defence, they are considered secondary metabolites. Hence their potential for having biotechnologically interesting features [127] . Polyketide synthases (PKS) and non-ribosomal peptide synthetases (NRPS) are examples of families of complex enzymatic machineries that have been proven to be responsible for the production of most bacterial bioactive molecules [128] . The search for genes related to these complexes can be made using simple and low-cost molecular techniques such as DNA extraction and amplification using specific primers [129, 130] . Early-on, genetic screenings can thus complement preliminary bioactivity screenings and help identify the most promising strains for use in further molecule isolation studies. In fact, this is important not only to help reduce the number of strains to work with, but also to discriminate promising strains belonging to the same species, as even phylogenetically close strains can have different genomic content regarding the presence of biosynthetic gene clusters [131] . Moreover, this approach has proven to be successful in helping select good candidates which ultimately showed interesting bioactive profiles, including the potential production of novel molecules [131] [132] [133] . Furthermore, with the increase in available data on sequenced bacterial genomes, genome mining techniques have rapidly evolved for detecting secondary metabolite gene clusters [134] . Several online platforms dedicated to the search for genes encoding core-biosynthetic enzymes are currently available, such as BAGEL [135] , NaPDos and antiSMASH [136] , amongst others. BAGEL can detect putative bacteriocins and ribosomally synthesized and post-translationally modified peptides (RiPPs) of gene clusters in bacterial genomes whereas NaPDos extracts C-and KS-domains to identify secondary metabolite genes in general. AntiSMASH is the most complete platform, as it uses a library of enzymes/protein domains that are normally seen in secondary metabolite biosynthetic pathways to identify possible hits with 44 different types of gene clusters [136] . These include, not only various types of PKS, NRPS and PKS/NRPS hybrids, but also other important secondary metabolite gene clusters for biosynthesis of compounds like RiPPs, terpenoids/isoprenoids, and ectoines, among others. This approach is already successfully assisting in discovering and characterize new natural products, as is the case for the macrolactams lobosamide A, B and C [72] , which were characterized with the help of antiSMASH and the polythioamide neothioviridamide [85] , whose biosynthetic cluster belongs to a cryptic RiPP and was heterogeneously expressed in S. avermitilis (discussed in Sections 2.2.1 and 2.2.3). Genome mining for secondary metabolite genes can also be applied in metagenomic data of still uncultured organisms, as well as to help unveil the biotechnological potential of unique and still under-explored bacterial groups, such as, for example, the planctomycetes [137] [138] [139] .

Because of the drawbacks imposed by traditional screening methodologies, biotechnological pharmaceutical companies have largely abandoned these assay models in favour of high-throughput screening (HTS) methodologies. HTS methodologies are characterized by rapid, high-volume testing of compounds, in the range of 10 5 to 10 6 molecules per day, and are inserted in a whole drug discovery strategy directed towards novel therapeutic leads [140] . HTS are easily miniaturized in 96-, 384-or 1,536-microwell plate formats and are generally based on cell or biochemical targets in which the response is measured as either an increase or a decrease of a signal. The signal measured is usually based on absorbance methods, e.g., fluorescence [141] . Non-conventional methodologies, genetic tools and HTS methodologies, are less labour demanding, improve the speed and capacity of testing, and discovering of novel bioactive molecules. They potentially allow the decrease of the needed time for obtainment of new pharmaceuticals, which is a fundamental aspect in the lengthy process of drug discovery.

The great chemical diversity present in natural molecules has been the impetus behind the discovery of novel therapeutics [142] . Yet, the isolation and characterization of novel natural molecules is a laborious, time consuming endeavour that requires particular expertise and competences [143] . This is mainly due to the presence of known and redundant compounds in crude extracts [144] . Thus, a strategy for recognizing and eliminating already known bioactive natural molecules in the early stage of the screening process is crucial. This process is called dereplication [145] .

The dereplication process analyses previously identified active samples in preliminary biological screenings through a combination of analytical and spectroscopic methods to putatively identify any possible known bioactive molecules present. In this section, current strategies for the dereplication of bioactive extracts will be explained.

Crude bacterial extracts are complex mixtures of organic molecules [146] , usually containing nutrients, primary and secondary metabolites [147] . Due to this complexity, in the dereplication process, crude extracts must first be fractionated prior to any spectroscopic analysis [145] . While many developed separation techniques exist, like thin-layer chromatography, gas chromatography and capillary electrophoresis to name but a few, the most commonly used techniques in the dereplication process pivot between high-performance liquid chromatography (HPLC) and ultra-high-performance liquid chromatography (UHPLC) [148] . The extensive use of HPLC systems in the isolation of natural products has allowed it to become a powerful and versatile tool, as HPLC systems can be easily hyphenated with detection techniques (like ultraviolet/visible (UV/Vis) detectors, mass (MS) and NMR spectrometers, see below) and copious amounts of data available, makes HPLC the de facto standard chromatographic technique for dereplication [142] . Still, while UHPLC systems are less used, they can operate at very high pressures with very small particle size columns, which grants them great sensitivity while diminishing sample and eluent volumes used and the analysis time [149] . However, both techniques allow for the use of compatible column types and chemical phases. Because of the chemical nature of most natural products, small molecules with molecular weights bellow 1000 Da and low or no polarity [147] , the best method for their separation is revered-phase chromatography which allows a longer retention time in the column during the polar and elution in the non-polar phase [150, 151] . The time that the metabolite is retained in the column, also called retention time, gives an important chromatographic property intrinsic to each molecule that can be used in its identification [145, 148, 152] .

In the dereplication process, molecules are identified due to intrinsic properties, like absorption peaks or molecular mass, which can be measured by a number of detection techniques. The most common techniques include, UV/Vis diode array detectors (DAD), mass spectrometers and NMR spectrometers [142] .

In UV/Vis spectroscopy, UV/vis spectra can be immediately acquired as part of the chromatographic separation of the extracts [147] . UV/vis spectra are normally obtained through the use of DAD, which can scan a range of wavelengths and produce the absorption spectrum. UV/Vis spectroscopy gives useful information on the molecules, such as chromophores present and the max absorption wavelength (λ max ), giving important structural information for the identification of yet unknown molecules [153] . Yet, but for the dereplication process, the full spectrum is a superior and more definitive approach, as it contains more information than just the λ max can give [148] . However, in the dereplication process, UV/vis spectra are normally used only as a secondary criterion. Currently, the principal criterion for identification is based on high resolution-MS (HRMS) [142] . MS is a destructive technique that provides the mass-to-charge ratio (m/z) of the ionized molecule or ionized fragments of the molecule. MS data is presented as spectrum of m/z and relative intensity. The m/z can be used to estimate the molecular mass of the molecule and thus, its molecular formula [154] . Additionally, as the ionization of the molecule may fragment it in smaller pieces, this fragmentation pattern can also be used in the identification of the molecule. Moreover, if it is a novel molecule, the fragmentation pattern can give useful information for structural elucidation of the molecule [155] . Initial dereplication efforts were based around low resolution-MS (LRMS) [156] . However, LRMS is ineffective in resolving between two very closely weight molecules, as LRMS can only confidently detect up to the integer of the mass. Thus, HRMS, which can give extremely accurate molecular masses [154] , was adopted. Nevertheless, an LC-DAD-MS dereplication only putatively identifies the compounds present in the extract, because of the possible existence of regioisomers or stereoisomers [148] . Therefore, full confirmation of the identity is only possible through NMR spectroscopy. NMR spectroscopy of natural products is normally performed on protons ( 1 H-NMR) and carbons ( 13 C-NMR) where the chemical shifts measured correlate with the position and type of each atom in the molecule. NMR has various advantages compared to MS, as it can analyse all kinds of small metabolites and samples can be recovered for further analyses. It is considered the universal detector for structure elucidation, has high analytical reproducibility and simplicity of sample preparation [142] and can be used for checking the purity of the sample, a problem that can arise from the common purification steps undertaken in most natural product isolation [145] . An example of this are lipids, problematic impurities that are undetectable in LC-DAD-MS analysis because they have low UV absorption, have difficulty of ionizing and high lipophilicity, which, 1 H-NMR can easily recognize by the presence of the large peak of the lipidic methylene chain [157] . Yet, for NMR spectroscopy, sample size is a limiting factor, as it may require up to milligrams of the sample [142] . In contrast, MS can work with attomolar concentrations of sample [158] . This limitation in NMR spectroscopy is especially important in the dereplication process, as crude extracts may only contain minute quantities of molecules.

Databases of natural products are critical to successfully complete the dereplication process [142] . Databases contain crucial information on natural products, including molecular weight, exact mass and fragmentation pattern, UV/vis λ max absorption or full spectra and NMR spectra or chemical shifts [148] . Databases of natural products should also contain relevant taxonomic information of the producer organism and known biological activity. For the purpose of identification of natural products, public domain and commercial databases are available. The most important commercial databases include Chemical Abstracts Service's Registry File (CAS) [159] , NaprAlert [160] , the Chapman & Hall Dictionary of Natural Products (DNP), AntiBase [161] , MarinLit [162] , the open-access databases Global Natural Products Social Networking (GNPS) [163, 164] , The Natural Products Atlas (NPAtlas) [165, 166] and Small Molecule Accurate Recognition Technology (SMART) [167, 168] . The CAS database comprises the largest online repository of chemical structures, including natural products. NaprAlert has significant resources for dereplicating the terrestrial sources. MarinLit is a database dedicated to marine natural products established by Professors John Blunt and Murray Munro. Records contain bibliographic information and the database can be searched by querying substructure, 13 C-and 1 H-NMR shift data, exact mass, chemical formula, or UV λ max absorption. AntiBase focuses on molecules from microorganisms and higher fungi. AntiBase incorporates molecular formula and mass, melting point, optical rotation, UV λ max absorption, 13 C and 1 H-NMR shift data and mass spectra. AntiBase also contains bioactivity data and information on origin, isolation and literature sources.

The DNP is considered the most complete natural product database, containing relevant bibliographic references [148] . The DNP contains information on exact mass and molecular formula, UV λ max absorption, biological sources and activity. Of the commercial databases, for marine bacterial natural products, MarinLit, AntiBase and the DNP and its subset on marine natural products (DMNP) are considered the most relevant databases for marine bacterial natural products dereplication. GNPS is an open-access database hosted at University of California, San Diego of LC and MS/MS spectra below m/z 2000 of natural products with data of over 18,000 compounds. GNPS also can detect sets of spectra from related molecules, even if the spectra used is not matched to any known compounds [142] . It allows the use of experimental MS/MS spectra as input in searches, allowing the direct dereplication of molecules present in extracts or chromatographic fractions without the need for determining the molecular formulae of their components. Additionally, the algorithm behind the platform allows networks of molecules based on their cosine similarity to be established, a process that has proved to be very useful in the identification of new members of known families of natural products. Bioactivity data can also be added to the process, allowing the direct correlation between the presence of certain components in samples and their bioactivity, using the so-called "bioactive molecular networking" (BMN) approach [169] .

GNPS molecular networking has been successfully applied to the discovery of several bioactive natural products, including the antimicrobial angucycline-derived polycyclic aromatic polyketide lugdunomycin (65) (Figure 7 ) [170] , and the aromatic polyketide accramycin A (66) [171] , both isolated from Streptomyces sp., as well as the antibacterial chlorinated cyclic hexapeptides noursamycins A-F (67) (68) (69) (70) (71) (72) , obtained from cultures of Streptomyces noursei NTR-SR4 [172] . NPAtlas is a database which includes over 25,500 compounds from microbial sources. It contains referenced data for structure, compound names, source organisms, isolation references, total syntheses, and instances of structural reassignment and is integrated with other natural product databases, like GNPS [165] . SMART is an NMR database [in particular, non-uniform sampling heteronuclear single quantum coherence (NUS HSQC)] assisted by a deep convolutional neural network (dCNN) to not only identify compounds, but for novel unidentified ones, placing them in natural product families with similar HSQC spectra, thus allowing for faster structural elucidation. As SMART is assisted by dCNN, as the size of the training set increases for a given compound class, so does its accuracy and capability of prediction of a new compound's structure improve [167] . Additionally, with further training, SMART has the potential to enable novel experimentation at the chemistry-biology interface, like predictions of biological activity and or target. The SMART technology in combination with GNPS was successfully applied recently to the discovery of symplocolide A (73), a new chimeric swinholide-like macrolide with cytotoxic properties against the NCI-H460 human lung cancer cell line obtained from extracts of the filamentous marine cyanobacterium Symploca sp. [173] .

Antibiotics 2020, 9, x FOR PEER REVIEW 22 of 32 for structure, compound names, source organisms, isolation references, total syntheses, and instances of structural reassignment and is integrated with other natural product databases, like GNPS [165] . SMART is an NMR database [in particular, non-uniform sampling heteronuclear single quantum coherence (NUS HSQC)] assisted by a deep convolutional neural network (dCNN) to not only identify compounds, but for novel unidentified ones, placing them in natural product families with similar HSQC spectra, thus allowing for faster structural elucidation. As SMART is assisted by dCNN, as the size of the training set increases for a given compound class, so does its accuracy and capability of prediction of a new compound's structure improve [167] . Additionally, with further training, SMART has the potential to enable novel experimentation at the chemistry-biology interface, like predictions of biological activity and or target. The SMART technology in combination with GNPS was successfully applied recently to the discovery of symplocolide A (73), a new chimeric swinholide-like macrolide with cytotoxic properties against the NCI-H460 human lung cancer cell line obtained from extracts of the filamentous marine cyanobacterium Symploca sp. [173] . 

It is evident that great heath challenges are still in need of novel pharmaceutical responses. Resistance of bacteria and fungi to antibiotics, of parasites like malaria to the available treatments, unavailability of medicines to treat new viruses and efficient drugs for cancer treatment, require additional research and development focus in discovering novel bioactive molecules. Oceans, home to a substantial portion of the world's biodiversity, are still underexplored, and are an important source of drugs and drug leads. Since 2014, several novel marine bacterial natural products, obtained mainly from Actinobacteria, Firmicutes and Proteobacteria, were described and reported in this review. In supplement to conventional methods, high-throughput analysis, like genome and metagenomic analysis and HTS, and the use of new dereplication and identification tools, will foster the discovery of new leads. This review shows that marine bacteria are key to the development of new pharmaceuticals, especially if combined with a rational, high-throughput approach. 

Global trends in antimicrobial resistance in animals in low-and middle-income countries

Global geographic trends in antimicrobial resistance: The role of international travel

WHO. Global Antimicrobial Resistance Surveillance System (GLASS) Report: Early Implementation

Global Priority List of Antibiotic-Resistant Bacteria to Guide Research, Discovery, and Development of New Antibiotics; World Health Organization

Population-Based Active Surveillance for Culture-Confirmed Candidemia-Four Sites

Simultaneous Emergence of Multidrug-Resistant Candida auris on 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological Analyses

Antifungal drug resistance: Mechanisms, epidemiology, and consequences for treatment

Azole antifungal resistance in Aspergillus fumigatus

Frequency and evolution of Azole resistance in Aspergillus fumigatus associated with treatment failure

The cost of antimicrobial resistance

Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria: A prospective study in Papua

Clinical features, diagnosis, and treatment of human African trypanosomiasis (sleeping sickness)

Management of trypanosomiasis and leishmaniasis

Medical need, scientific opportunity and the drive for antimalarial drugs

Evidence of Plasmodium falciparum Malaria Multidrug Resistance to Artemisinin and Piperaquine in Western Cambodia: Dihydroartemisinin-Piperaquine Open-Label Multicenter Clinical Assessment

Qinghaosu (artemisinin): Chemistry and pharmacology

Molecular and Cellular Biology of Viruses

Coronavirus Infections-More Than Just the Common Cold

The Challenges Imposed by Dengue, Zika, and Chikungunya to Brazil

The Ebola Epidemic: A Global Health Emergency

Host Factors in Coronavirus Replication

Human immunodeficiency virus infection (HIV)-associated rheumatic manifestations in thepre-and post-HAART eras

Emerging infectious diseases: Threats to human health and global stability

The One Health Concept: 10 Years Old and a Long Road Ahead

Antibiotic resistance is the quintessential One Health issue

Antibiotics in agriculture and the risk to human health: How worried should we be?

Global Burden of Disease Cancer Collaboration. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study

GBD 2015 Mortality; Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: A systematic analysis for the Global Burden of Disease Study

Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods

The molecular biology of cancer

A Review of the Underlying Mechanisms Resulting in the Tissue-Specific Tumorigenesis in Mutation Carriers

The Global Burden of Cancer

Microbial antitumor drugs: Natural products of microbial origin as anticancer agents

Why is cancer drug discovery so difficult?

Early history of wound treatment

The first 3500 years of aspirin history from its roots-A concise summary

Drugs from the deep: Marine natural products as drug candidates

A historical overview of natural products in drug discovery

Lessons from the past and charting the future of marine natural products drug discovery and chemical biology

The occurrence of two new prostaglandin derivatives (15-epi-PGA2 and its acetate, methyl ester) in the gorgonian Plexaura homomalla chemistry of coelenterates

Morphological and chemotaxonomic studies on Laurencia composita and L. okamurae (Ceramiales, Rhodophyta)

Tedanolide and the evolution of polyketide inhibitors of eukaryotic protein synthesis

Bioactive Marine Natural Products: Insights into Marine Microbes, Seaweeds, and Marine Sponges as Potential Sources of Drug Discovery

Marine sponges: Potential sources of new antimicrobial drugs

Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data

Large-scale production of pharmaceuticals by marine sponges: Sea, cell, or synthesis?

The discovery and development of marine compounds with pharmaceutical potential

Eribulin drug review

Marine natural products

Microbial symbionts of marine invertebrates: Opportunities for microbial biotechnology

The bryostatins

Isolation and structure of bryostatin 1

Identification of the putative bryostatin polyketide synthase gene cluster from "Candidatus Endobugula sertula", the uncultivated microbial symbiont of the marine bryozoan Bugula neritina

Marine natural products

Salinosporamide A: A highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus salinospora

Marine natural products

Marine Compounds and Cancer: The First Two Decades of XXI Century

Marine natural products

Marine natural products

Computational approaches to natural product discovery

Bacicyclin, a new antibacterial cyclic hexapeptide from Bacillus sp. strain BC028 isolated from Mytilus edulis

Anthracimycin B, a Potent Antibiotic against Gram-Positive Bacteria Isolated from Cultures of the Deep-Sea Actinomycete Streptomyces cyaneofuscatus M-169

Isolation and structure elucidation of lipopeptide antibiotic taromycin B from the activated taromycin biosynthetic gene cluster

Novel antifungal janthinopolyenemycins A and B from a co-culture of marine-associated Janthinobacterium spp. ZZ145 and ZZ148

Discovery, Biosynthesis, and Heterologous Production of Streptoseomycin, an Anti-Microaerophilic Bacteria Macrodilactone

Ansalactams B-D Illustrate Further Biosynthetic Plasticity within the Ansamycin Pathway

Antiproliferative and antiplasmodial compounds from selected Streptomyces species

Branimycins B and C, Antibiotics Produced by the Abyssal Actinobacterium Pseudonocardia carboxydivorans M-227

Genome-Directed Lead Discovery: Biosynthesis, Structure Elucidation, and Biological Evaluation of Two Families of Polyene Macrolactams against Trypanosoma brucei

Salinipostins A-K, long-chain bicyclic phosphotriesters as a potent and selective antimalarial chemotype

Mollemycin A: An antimalarial and antibacterial glyco-hexadepsipeptide-polyketide from an Australian marine-derived Streptomyces sp. (CMB-M0244)

Edrada-Ebel, R. Dereplication strategies for targeted isolation of new antitrypanosomal actinosporins A and B from a marine sponge associated-Actinokineospora sp. EG49

Gageostatins A-C, antimicrobial linear lipopeptides from a marine Bacillus subtilis

Gageotetrins A-C, noncytotoxic antimicrobial linear lipopeptides from a marine bacterium Bacillus subtilis

Non-cytotoxic antifungal agents: Isolation and structures of gageopeptides A-D from a Bacillus strain 109GGC020

Here a virus, there a virus, everywhere the same virus?

Viruses in the sea

Abyssomicin Monomers and Dimers from the Marine-Derived Streptomyces koyangensis SCSIO 5802

Phenolic polyketides from the marine alga-derived Streptomyces sp. OUCMDZ-3434

Antiviral Indolosesquiterpenoid Xiamycins C-E from a Halophilic Actinomycete

Coculture of Marine Streptomyces sp. With Bacillus sp. Produces a New Piperazic Acid-Bearing Cyclic Peptide

Polythioamide Compound Produced by Heterologous Expression of a Streptomyces sp

Structure elucidation and antitumour activity of a new macrolactam produced by marine-derived actinomycete Micromonospora sp. FIM05328

Integration of Genomic Data with NMR Analysis Enables Assignment of the Full Stereostructure of Neaumycin B, a Potent Inhibitor of Glioblastoma from a Marine-Derived Micromonospora

Activation and characterization of a cryptic gene cluster reveals a cyclization cascade for polycyclic tetramate macrolactams

Antiproliferative cyclodepsipeptides from the marine actinomycete Streptomyces sp. P11-23B downregulating the tumor metabolic enzymes of glycolysis, glutaminolysis, and lipogenesis

Marine Streptomyces sp. derived antimycin analogues suppress HeLa cells via depletion HPV E6/E7 mediated by ROS-dependent ubiquitin-proteasome system

Geranylpyrrol A and Piericidin F from Streptomyces sp. CHQ-64 DeltardmF

Neo-actinomycins A and B, natural actinomycins bearing the 5H-oxazolo [4-b] phenoxazine chromophore, from the marine-derived Streptomyces sp

and PM100118, new antitumor macrolides produced by a marine Streptomyces caniferus GUA-06-05-006A

Structure and activity of lobophorins from a turrid mollusk-associated Streptomyces sp

Isolation and Biosynthetic Analysis of Haliamide, a New PKS-NRPS Hybrid Metabolite from the Marine Myxobacterium Haliangium ochraceum

Cytotoxic indole alkaloids from Pseudovibrio denitrificans BBCC725

Bacterial Production of a Pederin Analogue by a Free-Living Marine Alphaproteobacterium

Single-disk antibiotic-sensitivity testing of staphylococci; an analysis of technique and results

Susceptibility test methods: Dilution and disk diffusion methods

Antibiotic susceptibility testing by a standardized single disk method

Evaluation of disk diffusion method for determining posaconazole susceptibility of filamentous fungi: Comparison with CLSI broth microdilution method

Antimicrobial Susceptibility Testing: A Review of General Principles and Contemporary Practices

Susceptibility Test Methods: Parasites

Visceral leishmaniasis: Experimental models for drug discovery

Identification of oxadiazoles as new drug leads for the control of schistosomiasis

The eradication of smallpox-an overview of the past, present, and future. Vaccine

Antiviral Strategies: The Present and Beyond

In vitro methods for testing antiviral drugs

Viral concentration determination through plaque assays: Using traditional and novel overlay systems

Plaque inhibition assay for drug susceptibility testing of influenza viruses

An antiviral drug screening system for enterovirus 71 based on an improved plaque assay: A potential high-throughput method

A standardized plaque reduction assay for determination of drug susceptibilities of cytomegalovirus clinical isolates

Identification of three antiviral inhibitors against Japanese encephalitis virus from library of pharmacologically active compounds 1280

Development of an Antiviral Screening Protocol: One-Stone-Two-Birds

Development of a luciferase based viral inhibition assay to evaluate vaccine induced CD8 T-cell responses

A new antiviral screening method that simultaneously detects viral replication, cell viability, and cell toxicity

An evaluation of folic acid antagonists in adults with neoplastic diseases: A study of 93 patients with incurable neoplasms

The clinical relevance of cancer cell lines

Trypan blue exclusion test of cell viability

Tetrazolium salts and formazan products in Cell Biology: Viability assessment, fluorescence imaging, and labeling perspectives

A high density assay format for the detection of novel cytotoxic agents in large chemical libraries

Cell Viability Assay: Fast, Sensitive and Flexible. Promega Notes Mag

Vitro Cytotoxicity and Cell Viability Assays: Principles, Advantages, and Disadvantages

Clonogenic cell survival assay

Simple Laboratory methods to measure cell proliferation using DNA synthesis property

The natural functions of secondary metabolites

Polyketide synthases and nonribosomal peptide synthetases: The emerging view from bacterial genomics

Marine actinomycetes related to the "Salinospora" group from the Great Barrier Reef sponge Pseudoceratina clavata

Nonribosomal peptide synthesis and toxigenicity of cyanobacteria

Planctomycetes as Novel Source of Bioactive Molecules

Diketopiperazines and other bioactive compounds from bacterial symbionts of marine sponges

The evolution of genome mining in microbes-A review

BAGEL4: A user-friendly web server to thoroughly mine RiPPs and bacteriocins

antiSMASH 5.0: Updates to the secondary metabolite genome mining pipeline

On the maverick Planctomycetes

Cultivation and functional characterization of 79 planctomycetes uncovers their unique biology

From genome mining to phenotypic microarrays: Planctomycetes as source for novel bioactive molecules

High-throughput screening assays for the identification of chemical probes

Design and Implementation of High Throughput Screening Assays

Dereplication: Racing to speed up the natural products discovery process

Thoughts and facts about antibiotics: Where we are now and where we are heading

The evolving role of natural products in drug discovery

Dereplication of microbial extracts and related analytical technologies

Construction of a natural product library containing secondary metabolites produced by actinomycetes

Current approaches and challenges for the metabolite profiling of complex natural extracts

Combined LC/UV/MS and NMR Strategies for the Dereplication of Marine Natural Products

Ultra high pressure liquid chromatography for crude plant extract profiling

Recent advances on HPLC/MS in medicinal plant analysis-An update covering 2011-2016

Recent advances on HPLC/MS in medicinal plant analysis

A study on retention "projection" as a supplementary means for compound identification by liquid chromatography-mass spectrometry capable of predicting retention with different gradients, flow rates, and instruments

Dereplication of microbial natural products by LC-DAD-TOFMS

A century of mass spectrometry: From atoms to proteomes

MS/MS networking guided analysis of molecule and gene cluster families

Fungal metabolite screening: Database of 474 mycotoxins and fungal metabolites for dereplication by standardised liquid chromatography-UV-mass spectrometry methodology

Evolving Trends in the Dereplication of Natural Product Extracts: New Methodology for Rapid, Small-Scale Investigation of Natural Product Extracts

High Sensitivity Quantitative Proteomics Using Automated Multidimensional Nano-flow Chromatography and Accumulated Ion Monitoring on Quadrupole-Orbitrap-Linear Ion Trap Mass Spectrometer

Chemical Abstracts Service's Registry File

The Natural Compound Identifier

A Database of the Marine Natural Products Literature

Sharing and community curation of mass spectrometry data with Global Natural Products Social Molecular Networking

Global Natural Products Social Networking (GNPS)

The Natural Products Atlas: An Open Access Knowledge Base for Microbial Natural Products Discovery

The Natural Products Atlas

Small Molecule Accurate Recognition Technology (SMART) to Enhance Natural Products Research

Small Molecule Accurate Recognition Technology (SMART)

Bioactivity-Based Molecular Networking for the Discovery of Drug Leads in Natural Product Bioassay-Guided Fractionation

Angucycline-Derived Molecule with Unprecedented Chemical Architecture

Accramycin A, a New Aromatic Polyketide, from the Soil Bacterium

Chlorinated Cyclohexapeptides Identified from Molecular Networking of Streptomyces noursei NTR-SR4

A Convolutional Neural Network-Based Approach for the Rapid Annotation of Molecularly Diverse Natural Products

This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license